跳至主要内容
临床试验/NCT01750645
NCT01750645Unknown不适用

Management of the Idiopathic Overactive Bladder With Intradetrusor Injection of Type-A Botulinum Toxin: Systematic Review of the Literature

Clínica Infantil Colsubsidio1 个研究点 分布在 1 个国家开始时间: 2012年7月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
发起方
试验地点
1
主要终点
Efficacy of the intervention for relieving the symptoms (urgency, frequency and urgency incontinence)

研究概览

简要总结

Overactive bladder is defined as a syndrome composed of urgency, increased urinary frequency, and sometimes urinary incontinence; its etiology may be characterized as neurogenic or non-neurogenic (i.e., idiopathic). This illness has a great impact in quality of life and one of the available treatments is the injection of Botulinum Toxin. This study aims to review the efficacy and safety of type-A Botulinum Toxin in the management of Idiopathic Overactive Bladder. A systematic search was performed in MEDLINE, EMBASE, CENTRAL and LILACS, and the controlled randomized clinical trials were chosen to review with the CONSORT criteria by independent reviewers. Outcomes analyzed were the efficacy of the intervention for relieving the symptoms (urgency, frequency and urgency incontinence), adverse events to treatment, change in quality of life and urodynamic measures.

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Controlled randomized clinical trials
  • Adult patients diagnosed with idiopathic overactive bladder
  • Language of the study: english

排除标准

  • Diagnosis of neurogenic overactive bladder
  • Patients under 18 years old
  • Use of Type-B Botulinum Toxin as the intervention
  • Other types of studies

研究组 & 干预措施

Intervention Group

干预措施: Intradetrusor Injection of Type-A Botulinum Toxin (Drug)

Control Group

干预措施: Other interventions analyzed according to protocol (Other)

结局指标

主要结局

Efficacy of the intervention for relieving the symptoms (urgency, frequency and urgency incontinence)

时间窗: Minimun follow-up period of 12 weeks

次要结局

  • Adverse events to treatment (urinary retention and urinary tract infections)(Minimun follow-up period of 12 weeks)
  • Change in quality of life(Minimun follow-up period of 12 weeks)
  • Change in urodynamic measures(Minimun follow-up period of 12 weeks)

研究者

发起方
Clínica Infantil Colsubsidio
申办方类型
Other
责任方
Principal Investigator
主要研究者

Hugo Enrique López, MD

MD

Clínica Infantil Colsubsidio

研究点 (1)

Loading locations...

相似试验